{"id":22864,"date":"2026-09-01T14:02:49","date_gmt":"2026-09-01T12:02:49","guid":{"rendered":"https:\/\/mic-site.labiux.com\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/"},"modified":"2026-10-16T22:27:53","modified_gmt":"2026-10-16T19:27:53","slug":"deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse","status":"publish","type":"post","link":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/","title":{"rendered":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113"},"content":{"rendered":"<div class=\"wp-block-labiux-legacy-html legacy-content\">\n<p>Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas vesel\u012bbas apsekojuma (EHIS) tre\u0161\u0101 vi\u013c\u0146a anal\u012bze par 26 ES valst\u012bm par\u0101d\u012bja, ka aptuveni 34,3% pieaugu\u0161o regul\u0101ri pa\u0161i \u0101rst\u0113jas ar bezrecep\u0161u medikamentiem, un \u0161\u012b tendence ir izteikt\u0101ka sievie\u0161u (39,7%) nek\u0101 v\u012brie\u0161u vid\u016b (28,5%) [1]. Tas liecina, ka itin bie\u017ei klients izv\u0113las lietot bezrecep\u0161u prets\u0101pju l\u012bdzek\u013cus bez farm\u0101cijas speci\u0101lista konsult\u0101cijas. Situ\u0101ciju saasina ar\u012b tas, ka vair\u0101k\u0101s Eiropas Savien\u012bbas valst\u012bs bezrecep\u0161u l\u012bdzek\u013cus var ieg\u0101d\u0101ties ne tikai aptiek\u0101s, bet ar\u012b lielveikalos un degvielas uzpildes stacij\u0101s.<\/p>\n<p>Probl\u0113ma nav pati pa\u0161\u0101rst\u0113\u0161an\u0101s. Atbild\u012bga pa\u0161apr\u016bpe ir norm\u0101la un v\u0113lama vesel\u012bbas apr\u016bpes sist\u0113mas da\u013ca. Probl\u0113ma ir zin\u0101\u0161anu tr\u016bkums, kas \u0161o izv\u0113li pavada. P\u0113t\u012bjumi konsekventi r\u0101da, ka pat\u0113r\u0113t\u0101ju zin\u0101\u0161anas par analg\u0113tisko l\u012bdzek\u013cu risku ir p\u0101rsteidzo\u0161i zemas: daudzi pieaugu\u0161ie nezina par paracetamola hepatotoksicit\u0101tes risku vai NPL ku\u0146\u0123a un zarnu trakta (KZT), kardiovaskul\u0101ru (KV) un nieru risku (2).<br \/>\nSa\u016bda Ar\u0101bij\u0101 veikt\u0101 aptauj\u0101 vair\u0101k nek\u0101 puse respondentu (54,5%) sp\u0113ja nosaukt tikai tr\u012bs vai maz\u0101k analg\u0113tisko l\u012bdzek\u013cu blakuspar\u0101d\u012bbas, kaut ar\u012b pa\u0161i tos regul\u0101ri lietoja (3). L\u012bdz\u012bgi rezult\u0101ti ir ar\u012b citos re\u0123ionos \u2013 starp zin\u0101\u0161an\u0101m un re\u0101lo praksi ir plaisa: cilv\u0113ki teor\u0113tiski zina, ka nedr\u012bkst p\u0101rsniegt devu vai kombin\u0113t prepar\u0101tus, ta\u010du praks\u0113 to tom\u0113r dara visbie\u017e\u0101k laika tr\u016bkuma, \u0113rt\u0101kas lieto\u0161anas d\u0113\u013c vai t\u0101d\u0113\u013c, ka v\u0113las p\u0113c iesp\u0113jas \u0101tr\u0101k mazin\u0101t simptomu (4).<br \/>\nTie\u0161i \u0161eit farmaceita loma k\u013c\u016bst iz\u0161\u0137iro\u0161a. Aptieka ir pieejam\u0101k\u0101 vesel\u012bbas apr\u016bpes iest\u0101de, un farmaceits ir pieejam\u0101kais vesel\u012bbas apr\u016bpes speci\u0101lists, pie kura v\u0113r\u0161as klienti (5). \u0160is raksts apkopo praktiski pielietojamu inform\u0101ciju par galvenaj\u0101m bezrecep\u0161u prets\u0101pju l\u012bdzek\u013cu grup\u0101m, bie\u017e\u0101kaj\u0101m k\u013c\u016bd\u0101m klientu izv\u0113l\u0113 un konsult\u0113\u0161anas pieej\u0101m, ko var izmantot farmaceits ikdienas darb\u0101 aptiek\u0101.<\/p>\n<p><a href=\"https:\/\/dati.zva.gov.lv\/zalu-registrs\/?iss=1&amp;q=Xeldaxin&amp;IK-1=1&amp;IK-2=2&amp;NAC=on&amp;SAT=on&amp;DEC=on&amp;ESC=on&amp;ESI=on&amp;PIM=on&amp;RNE=on\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-large wp-image-37523\" src=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/09\/Xeldaxin-ban-990x1400-1-724x1024.png\" alt=\"\" width=\"618\" height=\"874\"><\/a><\/p>\n<h3>Galven\u0101s bezrecep\u0161u prets\u0101pju l\u012bdzek\u013cu grupas<\/h3>\n<p><strong>Paracetamols (acetaminof\u0113ns)<\/strong><\/p>\n<p>\nParacetamols ir pirm\u0101s izv\u0113les analg\u0113tiskais un antipir\u0113tiskais l\u012bdzeklis vairumam pacientu, jo tam nav noz\u012bm\u012bgas ietekmes uz ku\u0146\u0123a un zarnu traktu, nieru asinsriti vai tromboc\u012btu funkciju. T\u0101 galvenais riska faktors ir aknu toksicit\u0101te, kas rodas devu p\u0101rsnieg\u0161anas gad\u012bjum\u0101, un tie\u0161i \u0161is risks aptiek\u0101 tiek nepietiekami nov\u0113rt\u0113ts, jo paracetamols bie\u017ei tiek uztverts k\u0101 \u201cpiln\u012bgi dro\u0161s\u201d tie\u0161i t\u0101p\u0113c, ka tas ir bezrecep\u0161u prepar\u0101ts, to dr\u012bkst lietot gr\u016btniec\u012bbas laik\u0101 un tas ir relat\u012bvi ilgi z\u0101\u013cu tirg\u016b. Re\u0101ls kl\u012bnisks izaicin\u0101jums ir tas, ka paracetamols ir viena no sast\u0101vda\u013c\u0101m da\u017e\u0101dos kombin\u0113tos prepar\u0101tos (pretsaaukst\u0113\u0161an\u0101s l\u012bdzek\u013cos), kas rada augstu net\u012b\u0161as p\u0101rdoz\u0113\u0161anas risku, kad klients vienlaic\u012bgi lieto vair\u0101kus produktus, nesaprotot, ka tie visi satur to pa\u0161u akt\u012bvo vielu (6).<\/p>\n<p><strong>Nestero\u012bdie pretiekaisuma l\u012bdzek\u013ci (NPL)<\/strong><br \/>\n\u0160aj\u0101 grup\u0101 ietilpst ibuprof\u0113ns, diklofenaks, naproks\u0113ns un deksketoprof\u0113ns. NPL ir efekt\u012bv\u0101ki par paracetamolu, ja past\u0101v izteikts iekaisums, piem\u0113ram, artr\u012bts, k\u0101 ar\u012b musku\u013cu un kaulu traumas, menstru\u0101lo s\u0101pju gad\u012bjum\u0101, ta\u010du \u0161\u012b terapeitisk\u0101 priek\u0161roc\u012bba n\u0101k kop\u0101 ar noz\u012bm\u012bgiem dro\u0161uma kompromisiem. Ku\u0146\u0123a un zarnu trakta blakuspar\u0101d\u012bbas sv\u0101rst\u0101s no vieglas dispepsijas l\u012bdz nopietnai, dz\u012bv\u012bbai b\u012bstamai asi\u0146o\u0161anai, un risks ir \u012bpa\u0161i augsts gados vec\u0101kiem cilv\u0113kiem un pacientiem ar peptisko \u010d\u016blu anamn\u0113z\u0113 (7). Sirds un asinsvadu sist\u0113mas dro\u0161ums ar\u012b ir noz\u012bm\u012bgs apsv\u0113rums, jo ilgsto\u0161a NPL lieto\u0161ana saist\u012bta ar paaugstin\u0101tu miokarda infarkta un insulta risku, un \u0161\u012b ietekme par\u0101d\u0101s pat \u012bslaic\u012bgas vai neregul\u0101ras lieto\u0161anas gad\u012bjum\u0101 (8). Kait\u0113jums nier\u0113m var rasties \u012bpa\u0161i pacientiem ar jau eso\u0161u nieru slim\u012bbu, sirds mazsp\u0113ju vai tiem, kas vienlaic\u012bgi lieto diur\u0113tiskos l\u012bdzek\u013cus \u2013 \u0161\u0101da kombin\u0101cija var paaugstin\u0101t hospitaliz\u0101cijas risku sirds mazsp\u0113jas d\u0113\u013c (9).<\/p>\n<p><strong>Acetilsalicilsk\u0101be (aspir\u012bns)<\/strong><br \/>\nAcetilsalicilsk\u0101be k\u0101 prets\u0101pju l\u012bdzeklis bezrecep\u0161u z\u0101\u013cu segment\u0101 tiek lietota ret\u0101k nek\u0101 kardioprofilaksei paredz\u0113taj\u0101s mazaj\u0101s dev\u0101s, ta\u010du analg\u0113tisk\u0101s dev\u0101s t\u0101 saglab\u0101 visus NPL rakstur\u012bgos ku\u0146\u0123a un zarnu trakta riskus, un papildus neatgriezeniski kav\u0113 tromboc\u012btu agreg\u0101ciju, kas noz\u012bm\u0113 paaugstin\u0101tu asi\u0146o\u0161anas risku kombin\u0101cij\u0101 ar antikoagulantiem vai citiem NPL. Svar\u012bgi atcer\u0113ties, ka acetilsalicilsk\u0101be b\u0113rniem un pusaud\u017eiem ar v\u012brusinfekcij\u0101m ir kontrindic\u0113ta Reja sindroma riska d\u0113\u013c.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-large wp-image-37520\" src=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/09\/tabula-1024x615.jpg\" alt=\"\" width=\"618\" height=\"371\">\n<\/p>\n<h3>At\u0161\u0137ir\u012bbas starp atsevi\u0161\u0137iem NPL<\/h3>\n<p>\nLai gan visiem NPL ir kop\u012bgs darb\u012bbas meh\u0101nisms (ciklooksigen\u0101zes inhib\u012bcija), starp konkr\u0113tiem prepar\u0101tiem past\u0101v noz\u012bm\u012bgas praktiskas at\u0161\u0137ir\u012bbas. Ibuprof\u0113ns maz\u0101k\u0101s dev\u0101s tiek uzskat\u012bts par vienu no relat\u012bvi saudz\u0113jo\u0161\u0101kiem l\u012bdzek\u013ciem attiec\u012bb\u0101 uz KZT un kardiovaskul\u0101ru risku, t\u0101p\u0113c tas bie\u017ei ir pirm\u0101s izv\u0113les NPL veselam pieaugu\u0161ajam bez papildu riska faktoriem. Diklofenaks un liel\u0101kas ibuprof\u0113na devas vair\u0101k palielina sirds un asinsvadu risku, kas praktiski tuvojas selekt\u012bvo COX-2 inhibitoru riska profilam (8). Naproks\u0113ns sal\u012bdzin\u0101jum\u0101 ar citiem NPL rada maz\u0101ku sirds un asinsvadu risku, ta\u010du tas nemazina KZT blakuspar\u0101d\u012bbas, un pacientiem ar paaugstin\u0101tu asi\u0146o\u0161anas risku joproj\u0101m nepiecie\u0161ama piesardz\u012bba (9).\n<\/p>\n<h3>Bie\u017ei nepaman\u012bta mijiedarb\u012bba ar citiem medikamentiem<\/h3>\n<p>\nViena no praktiski noz\u012bm\u012bg\u0101k\u0101m, ta\u010du reti apspriest\u0101m t\u0113m\u0101m ir t\u0101 saukt\u0101 \u201ctr\u012bsk\u0101r\u0161\u0101 trieciena\u201d (ang\u013cu triple whammy) mijiedarb\u012bba, kad notiek NPL vienlaic\u012bga lieto\u0161ana kop\u0101 ar AKE inhibitoru vai angiotens\u012bna receptoru blokatoru un diur\u0113tisku l\u012bdzekli. \u0160\u012b kombin\u0101cija noz\u012bm\u012bgi paaugstina ak\u016bta nieru boj\u0101juma risku, jo katrs no trim komponentiem atsevi\u0161\u0137i ietekm\u0113 nieru asinsriti vai \u0161\u0137idruma l\u012bdzsvaru, un to summ\u0101rais efekts var b\u016bt daudz izteikt\u0101ks nek\u0101 katra l\u012bdzek\u013ca atsevi\u0161\u0137a darb\u012bba (9). T\u0101 k\u0101 liela da\u013ca gados vec\u0101ku pacientu regul\u0101ri lieto tie\u0161i \u0161o kombin\u0101ciju hipertensijas vai sirds mazsp\u0113jas d\u0113\u013c, farmaceitam \u0161is jaut\u0101jums b\u016btu j\u0101uzdod m\u0113r\u0137tiec\u012bgi ikreiz, kad klients ar zin\u0101mu hipertensiju vai sirds slim\u012bbu l\u016bdz ieteikumu par NPL.<br \/>\nCitas noz\u012bm\u012bgas mijiedarb\u012bbas ietver NPL kop\u0101 ar antikoagulantiem (varfar\u012bns, tie\u0161as darb\u012bbas peror\u0101lie antikoagulanti) vai antiagregantiem, kas paaugstina asi\u0146o\u0161anas risku. NPL kop\u0101 ar sist\u0113miskiem kortikostero\u012bdiem vair\u0101kk\u0101rt palielina KZT \u010d\u016blas un asi\u0146o\u0161anas risku. Paracetamola gad\u012bjum\u0101 noz\u012bm\u012bg\u0101k\u0101 mijiedarb\u012bba ir ar varfar\u012bnu, jo regul\u0101ra lielas paracetamola devas lieto\u0161ana var pastiprin\u0101t varfar\u012bna antikoagulanta efektu, kas prasa piesardz\u012bbu INR kontrol\u0113 pacientam.\n<\/p>\n<h3>Peror\u0101lo prets\u0101pju l\u012bdzek\u013cu iedarb\u012bbas \u0101trums<\/h3>\n<p>\nPrets\u0101pju efekta iest\u0101\u0161an\u0101s \u0101trums liel\u0101 m\u0113r\u0101 ir atkar\u012bgs no t\u0101, cik \u0101tri akt\u012bv\u0101 viela uzs\u016bcas un sasniedz maksim\u0101lo koncentr\u0101ciju asin\u012bs (Tmax). Metaanal\u012bzes un randomiz\u0113ti p\u0113t\u012bjumi par prets\u0101pju l\u012bdzek\u013cu z\u0101\u013cu formu saist\u012bbu ar z\u0101\u013cu efektivit\u0101ti ak\u016btu s\u0101pju gad\u012bjum\u0101 liecina, ka \u0161\u0137\u012bsto\u0161\u0101s aspir\u012bna, diklofenaka, deksketoprof\u0113na un ibuprof\u0113na formas nodro\u0161ina lab\u0101ku prets\u0101pju efektu nek\u0101 standarta formas (14). T\u0101pat konstat\u0113ts, ka zob\u0101rstniec\u012bb\u0101 \u0101tras darb\u012bbas ibuprof\u0113na 200 mg deva bija tikpat efekt\u012bva k\u0101 standarta 400 mg deva, ta\u010du ar \u0101tr\u0101ku iedarb\u012bbas s\u0101kumu (14).<br \/>\nDeksketoprof\u0113ns uzskat\u0101ms par vienu no NPL ar \u0101tr\u0101ko darb\u012bbas s\u0101kumu \u2013 t\u0101 trometamola s\u0101ls forma ir \u016bden\u012b \u0161\u0137\u012bsto\u0161a, kas pa\u0101trina uzs\u016bk\u0161anos. Sal\u012bdzino\u0161os p\u0113t\u012bjumos laiks l\u012bdz s\u0101pju samazin\u0101jumam par vismaz 50% p\u0113c gudr\u012bbas zoba izrau\u0161anas bija \u012bs\u0101ks pacientiem, kuri sa\u0146\u0113ma peror\u0101lu deksketoprof\u0113nu, nek\u0101 tiem, kuri lietoja peror\u0101lu ibuprof\u0113nu (vid\u0113ji 0,9 pret 2,1 stundu) [15]. \u0160\u0137\u012bdumam sal\u012bdzin\u0101jum\u0101 ar tablet\u0113m koncentr\u0101cijas p\u012b\u0137is asin\u012bs nov\u0113rots \u0101tr\u0101k un tas ir augst\u0101ks, kas var liecin\u0101t par \u0101tr\u0101ku analg\u0113tisko efektu.<br \/>\nNaproks\u0113nam un diklofenakam rakstur\u012bgs l\u0113n\u0101ks iedarb\u012bbas s\u0101kums, ta\u010du ilg\u0101ks darb\u012bbas laiks, savuk\u0101rt paracetamolam iedarb\u012bba parasti iest\u0101jas 30\u201360 min\u016b\u0161u laik\u0101, ar m\u0113renu prets\u0101pju, bet v\u0101ju pretiekaisuma efektu.\n<\/p>\n<h3>Deksketoprof\u0113na dro\u0161uma profils ak\u016btu s\u0101pju \u0101rst\u0113\u0161an\u0101<\/h3>\n<p>\nDeksketoprof\u0113na trometamols ir ketoprof\u0113na akt\u012bv\u0101 S-(+)-enantiom\u0113ra \u016bden\u012b \u0161\u0137\u012bsto\u0161s s\u0101ls. Pieejamie dati liecina, ka tie\u0161i \u0161is enantiom\u0113rs galvenok\u0101rt nodro\u0161ina ketoprof\u0113na analg\u0113tisko un pretiekaisuma iedarb\u012bbu. \u0145emot v\u0113r\u0101 pieaugo\u0161o uzman\u012bbu NPL dro\u0161uma profilam, aktu\u0101li ir ar\u012b dati par deksketoprof\u0113na panes\u012bbu ne tikai kontrol\u0113tos kl\u012bniskajos p\u0113t\u012bjumos, bet ar\u012b ikdienas prim\u0101r\u0101s apr\u016bpes praks\u0113.<br \/>\nProspekt\u012bv\u0101 kohortas p\u0113t\u012bjum\u0101 tika iek\u013cauti 7337 pacienti ar da\u017e\u0101das izcelsmes viegl\u0101m vai vid\u0113ji stipr\u0101m ak\u016bt\u0101m s\u0101p\u0113m (vecuma medi\u0101na \u2013 46 gadi). Terapija tika ordin\u0113ta atbilsto\u0161i attiec\u012bgo z\u0101\u013cu aprakstiem, un pacientu l\u012bdzest\u012bba bija augsta. Deksketoprof\u0113nu sa\u0146\u0113ma 5429 pacienti \u2013 liel\u0101k\u0101 p\u0113t\u012bjuma grupa. Sal\u012bdzin\u0101jumam tika izmantoti pacienti, kuri lietoja diklofenaku, ibuprof\u0113nu, paracetamolu, metamizolu, aceklofenaku, naproks\u0113nu, piroksik\u0101mu vai deksibuprof\u0113nu. Visbie\u017e\u0101kie prets\u0101pju terapijas iemesli bija kaulu un musku\u013cu s\u0101pes, galvass\u0101pes, dismenoreja un odontog\u0113nas s\u0101pes.<br \/>\nS\u0101pju intensit\u0101te tika v\u0113rt\u0113ta ar 100 mm vizu\u0101lo analogo skalu (VAS) pirms terapijas, k\u0101 ar\u012b 1. un 7. \u0101rst\u0113\u0161anas dien\u0101. Paral\u0113li tika re\u0123istr\u0113tas nev\u0113lam\u0101s blakuspar\u0101d\u012bbas, kas \u013c\u0101va sal\u012bdzin\u0101t da\u017e\u0101du analg\u0113tisko l\u012bdzek\u013cu panes\u012bbu re\u0101los kl\u012bnisk\u0101s prakses apst\u0101k\u013cos.<br \/>\nDeksketoprof\u0113na grup\u0101 blakuspar\u0101d\u012bbas re\u0123istr\u0113tas 3,6% pacientiem, kas bija otrs zem\u0101kais r\u0101d\u012bt\u0101js starp vis\u0101m sal\u012bdzin\u0101taj\u0101m grup\u0101m. V\u0113l ret\u0101k (2,7%) blakuspar\u0101d\u012bbas bija tikai apvienotaj\u0101 metamizola vai paracetamola lietot\u0101ju grup\u0101, savuk\u0101rt liel\u0101kais bie\u017eums (8,2%) konstat\u0113ts aceklofenaka vai diklofenaka lietot\u0101ju grup\u0101. At\u0161\u0137ir\u012bbas starp grup\u0101m bija statistiski noz\u012bm\u012bgas. T\u0101pat k\u0101 citiem NPL, ar\u012b \u0161eit domin\u0113ja ar KZT saist\u012btas blakuspar\u0101d\u012bbas \u2013 t\u0101s nov\u0113rotas 3,5% dal\u012bbnieku un veidoja 84% visu re\u0123istr\u0113to nev\u0113lamo reakciju. Iev\u0113rojami ret\u0101k nov\u0113rotas nervu sist\u0113mas reakcijas (0,4% pacientu) un \u0101das reakcijas (0,1% pacientu).<br \/>\nNo kopum\u0101 332 zi\u0146otaj\u0101m blakuspar\u0101d\u012bb\u0101m 303 (91,3%) klasific\u0113tas k\u0101 vieglas vai vid\u0113ji smagas, un tikai 11 gad\u012bjumi (3,3%) tika uzskat\u012bti par smagiem. Lai objekt\u012bvi sal\u012bdzin\u0101tu KZT blakuspar\u0101d\u012bbu risku starp grup\u0101m, statistiskaj\u0101 anal\u012bz\u0113 tika \u0146emts v\u0113r\u0101 pacienta vecums, dzimums, iepriek\u0161\u0113ja NPL lieto\u0161ana, gastroprotekt\u012bvo l\u012bdzek\u013cu lieto\u0161ana un prets\u0101pju terapijas ordin\u0113\u0161anas iemesls. Par atsauces grupu izmantota metamizola un paracetamola grupa. Deksketoprof\u0113na 95% ticam\u012bbas interv\u0101ls ietv\u0113ra v\u0113rt\u012bbu 1, t\u0101p\u0113c \u0161ajos datos statistiski noz\u012bm\u012bgs KZT blakuspar\u0101d\u012bbu riska pieaugums sal\u012bdzin\u0101jum\u0101 ar atsauces grupu netika pier\u0101d\u012bts.<br \/>\nP\u0113t\u012bjuma v\u0113rt\u012bba sl\u0113pjas t\u0101 dizain\u0101, jo ieg\u016btie dati atspogu\u013co z\u0101\u013cu lieto\u0161anu re\u0101l\u0101s prim\u0101r\u0101s apr\u016bpes praks\u0113 pacientiem ar bie\u017ei sastopamiem ak\u016btu s\u0101pju veidiem.<br \/>\nDeksketoprof\u0113nam nov\u0113rotais sal\u012bdzino\u0161i mazais kop\u0113jais blakuspar\u0101d\u012bbu bie\u017eums un p\u0101rsvar\u0101 vieglais vai vid\u0113ji smagais reakciju raksturs sniedz papildu pier\u0101d\u012bjumus t\u0101 labv\u0113l\u012bgajam panes\u012bbas profilam \u012bslaic\u012bgas terapijas kontekst\u0101. Vienlaikus j\u0101uzsver, ka KZT reakcijas saglab\u0101j\u0101s k\u0101 domin\u0113jo\u0161\u0101 NPL blakuspar\u0101d\u012bbu grupa neatkar\u012bgi no konkr\u0113t\u0101s vielas (16).\n<\/p>\n<h3>Riska grupas<\/h3>\n<p>\nTurpm\u0101k min\u0113tas vair\u0101kas pacientu grupas, kuru p\u0101rst\u0101vjiem farmaceitisk\u0101s apr\u016bpes ietvaros nedr\u012bkst izv\u0113l\u0113ties bezrecep\u0161u prets\u0101pju l\u012bdzekli, neuzdodot papildu jaut\u0101jumus.\n<\/p>\n<ul>\n<li>Gados vec\u0101ki pacienti \u2013 paaugstin\u0101ts NPL izrais\u012btas KZT asi\u0146o\u0161anas, nieru darb\u012bbas trauc\u0113jumu un sirds mazsp\u0113jas risks, k\u0101 ar\u012b bie\u017ea polifarm\u0101cija, kas palielina mijiedarb\u012bbu iesp\u0113jam\u012bbu.<\/li>\n<li>Gr\u016btnieces un sievietes, kas baro b\u0113rnu ar kr\u016bti. NPL tre\u0161aj\u0101 trimestr\u012b ir kontrindic\u0113ti aug\u013ca priek\u0161laic\u012bgas ductus arteriosus sl\u0113g\u0161an\u0101s riska d\u0113\u013c. Paracetamols paliek pirm\u0101s izv\u0113les l\u012bdzeklis, ta\u010du ar\u012b tam j\u0101iev\u0113ro ieteicam\u0101 deva.<\/li>\n<li>Pacienti ar peptisko \u010d\u016blu anamn\u0113z\u0113 vai akt\u012bviem KZT simptomiem \u2013 no NPL princip\u0101 j\u0101izvair\u0101s vai j\u0101lieto tikai kop\u0101 ar gastroprotekt\u012bvu terapiju un \u0101rsta uzraudz\u012bb\u0101.<\/li>\n<li>Pacienti ar nieru vai aknu mazsp\u0113ju \u2013 NPL nieru mazsp\u0113jas gad\u012bjum\u0101 un paracetamols aknu mazsp\u0113jas gad\u012bjum\u0101 prasa devas korekciju vai piln\u012bgu izvair\u012b\u0161anos.<\/li>\n<li>Antikoagulantu vai antiagregantu lietot\u0101ji \u2013 NPL un acetilsalicilsk\u0101be noz\u012bm\u012bgi paaugstina asi\u0146o\u0161anas risku.<\/li>\n<li>B\u0113rni \u2013 devas j\u0101apr\u0113\u0137ina p\u0113c \u0137erme\u0146a masas. Vec\u0101kiem bie\u017ei tr\u016bkst skaidr\u012bbas par pareizu devu m\u0113r\u012b\u0161anu, kas rada gan p\u0101r\u0101k mazas devas, gan p\u0101rdoz\u0113\u0161anas risku.<\/li>\n<li>Pacienti ar sirds mazsp\u0113ju vai nekontrol\u0113tu hipertensiju \u2013 NPL var pastiprin\u0101t \u0161\u0137idruma aizturi un asinsspiediena kontroli, tostarp mazinot da\u017eu antihipertens\u012bvo z\u0101\u013cu efektivit\u0101ti (11).<\/li>\n<\/ul>\n<h3>Kad pacienta k\u013c\u016bda k\u013c\u016bst par farmaceita iesp\u0113ju<\/h3>\n<p><strong>K\u013c\u016bda Nr. 1<\/strong><\/p>\n<p>\nPacients uzskata, ka paracetamols ir \u201cdabisk\u0101ks\u201d par ibuprof\u0113nu, t\u0101p\u0113c maz\u0101k kait\u012bgs.<br \/>\n\u0160is pie\u0146\u0113mums ir pla\u0161i izplat\u012bts pacientu vid\u016b, ta\u010du tas ir nepatiess \u2013 abiem prepar\u0101tiem ir at\u0161\u0137ir\u012bgi, nevis hierarhiski riska profili. Paracetamola risks bie\u017ei tiek nov\u0113rt\u0113ts zem\u0101k par re\u0101lo l\u012bmeni gan pacientu, gan pat da\u017ek\u0101rt vesel\u012bbas apr\u016bpes speci\u0101listu vid\u016b.<br \/>\n<strong>K\u013c\u016bda Nr. 2<\/strong><br \/>\nNezin\u0101\u0161ana, ka vair\u0101ki produkti satur vienu un to pa\u0161u akt\u012bvo vielu. Klients, kur\u0161 vienlaic\u012bgi lieto pretsaaukst\u0113\u0161an\u0101s prepar\u0101tu un atsevi\u0161\u0137i paracetamola tableti s\u0101pju mazin\u0101\u0161anai, var nemanot p\u0101rsniegt maksim\u0101lo dienas devu. \u0160\u012b ir viena no bie\u017e\u0101k\u0101m un viegl\u0101k nov\u0113r\u0161am\u0101m k\u013c\u016bd\u0101m, t\u0101d\u0113\u013c tie\u0161i j\u0101jaut\u0101: &#8220;K\u0101du medikamentu v\u0113l lietojat pret saaukst\u0113\u0161anos, drudzi vai s\u0101p\u0113m?&#8221;.<br \/>\n<strong>K\u013c\u016bda Nr. 3<\/strong><br \/>\nDevas p\u0101rsnieg\u0161ana ar pie\u0146\u0113mumu &#8220;vair\u0101k = efekt\u012bv\u0101k&#8221;. Ja s\u0101pes nemazin\u0101s p\u0113c ieteicam\u0101s devas lieto\u0161anas, klienta pirm\u0101 reakcija bie\u017ei ir devas vai lieto\u0161anas bie\u017euma palielin\u0101\u0161ana, nevis terapijas piem\u0113rot\u012bbas v\u0113rt\u0113\u0161ana vai s\u0101pju c\u0113lo\u0146a papildus izmekl\u0113\u0161ana.<br \/>\n<strong>K\u013c\u016bda Nr. 4<\/strong><br \/>\nIlgsto\u0161a lieto\u0161ana bez st\u0101vok\u013ca v\u0113rt\u0113\u0161anas. Bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci tiek pozicion\u0113ti \u012bslaic\u012bgai lieto\u0161anai, ta\u010du praks\u0113 klienti tos bie\u017ei lieto ned\u0113\u013c\u0101m vai m\u0113ne\u0161iem bez atk\u0101rtotas konsult\u0101cijas, un tie\u0161i t\u0101d\u0113\u013c rodas vairums NPL uzkr\u0101\u0161an\u0101s risku.<br \/>\n<strong>K\u013c\u016bda Nr. 5<\/strong><br \/>\nKombin\u0113\u0161ana ar recep\u0161u medikamentiem bez mijiedarb\u012bbas v\u0113rt\u0113\u0161anas. Piem\u0113ram, NPL kombin\u0101cija ar antikoagulantiem, kortikostero\u012bdiem vai SSAI grupas antidepresantiem noz\u012bm\u012bgi paaugstina asi\u0146o\u0161anas risku, ta\u010du klienti reti piev\u0113r\u0161 tam uzman\u012bbu, jo uztver bezrecep\u0161u z\u0101les k\u0101 &#8220;nenoz\u012bm\u012bgas&#8221; sal\u012bdzin\u0101jum\u0101 ar recep\u0161u z\u0101l\u0113m.<br \/>\nBezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ir efekt\u012bvi un dro\u0161i pa\u0161apr\u016bp\u0113, ta\u010du to \u0161\u0137ietam\u0101 vienk\u0101r\u0161\u012bba rada nepamatotu p\u0101rliec\u012bbu par riska tr\u016bkumu. Farmaceita loma nav tikai z\u0101\u013cu izsnieg\u0161ana, bet gan struktur\u0113ta, \u0101tra riska izv\u0113rt\u0113\u0161ana un pareiz\u0101 medikamenta izv\u0113le \u2013 pacienta st\u0101vok\u013ca, blakusslim\u012bbu, citu lietoto medikamentu un s\u0101pju rakstura kontekst\u0101. Da\u017eu m\u0113r\u0137tiec\u012bgu jaut\u0101jumu uzdo\u0161ana var b\u016btiski samazin\u0101t nov\u0113r\u0161amu blakuspar\u0101d\u012bbu skaitu un vienlaikus stiprin\u0101t klienta uztic\u012bbu aptiekas k\u0101 pirm\u0101 pieturas punkta lomai vesel\u012bbas apr\u016bpes sist\u0113m\u0101.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-large wp-image-37521\" src=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/09\/att-1024x718.jpg\" alt=\"\" width=\"618\" height=\"433\"><\/p>\n<p><strong>\u0112rika P\u0113tersone,<\/strong><br \/>\nsertific\u0113ta farmaceite<\/p>\n<p><strong>V\u0113res<\/strong><br \/>\n<em>1. Beyond pain relief: a comprehensive review of analgesic self-medication and its broad implications. International Review of Psychiatry\/Taylor &amp; Francis, 2025.<\/em><br \/>\n<em>2. Pharmacist-guided selection of OTC analgesics. U.S. Pharmacist, 2026.<\/em><br \/>\n<em>3. Frequency and knowledge of analgesics self-use and their adverse effects in the Eastern province of Saudi Arabia. Cureus, 2023.<\/em><br \/>\n<em>4. Discrepancy between knowledge and practice of self-medication among adults in Dhaka, Bangladesh in 2023. Health Science Reoprts, 2025.<\/em><br \/>\n<em>5. Prevent misuse and abuse of OTC medications. Pharmacy Times, 2026.<\/em><br \/>\n<em>6. Most US adults regularly use OTC and prescription medication. Drug Topics, 2026.<\/em><br \/>\n<em>7. Ahsan M. U. et al. NSAID-associated renal injury: mechanisms, risks, and safer strategies. Scientific Archives, 2025.<\/em><br \/>\n<em>8. The hidden cardiac risk in America\u2019s most used OTC painkillers. MDLinx, 2026.<\/em><br \/>\n<em>9. Balancing pain relief and safety: gastrointestinal and cardiovascular risk assessment in NSAID users and the role of gastroprotective co-therapy. PMC, 2025.<\/em><br \/>\n<em>10. Community pharmacists\u2019 preparedness to control OTC medication abuse in Saudi Arabia: a nationwide cross-sectional survey-based study. PMC, 2025.<\/em><br \/>\n<em>11. A comprehensive review of over-the-counter (OTC) medications: Benefits, risks, misuse, and regulatory perspectives. GSC Biological and Pharmaceutical Sciences, 2025.<\/em><br \/>\n<em>12. Prevalence, knowledge, attitudes, and practices concerning self-medication with OTC drugs among university students in Jordan. PMC, 2025.<\/em><br \/>\n<em>13. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database of Systematic Reviews, 2011.<\/em><br \/>\n<em>14. Faster, higher, stronger? Evidence for formulation and efficacy for ibuprofen in acute pain. Pain, 2014.<\/em><br \/>\n<em>15. Bioequivalence evaluation of two oral formulations of Dexketoprofen-trometamol (solution and tablets) in healthy subjects: Results from a randomized, single-blind, crossover study. Trends in Medicine, 2019.<\/em><br \/>\n<em>16. Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care. Methods and Findings in Experimental and Clinical Pharmacology, 2009.<\/em><\/p>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"mic_cinema_image":0,"mic_focus":"","mic_cinema_focus":"","footnotes":"","_labiux_rail":0},"categories":[70,76,73,191],"tags":[2911],"mic_flag":[64],"class_list":["post-22864","post","type-post","status-publish","format-standard","hentry","category-farmacijas-zinas","category-jaunakie-raksti","category-medikamentu-zinas","category-reklamraksts","tag-deksketoprofens","mic_flag-reklamraksts"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas vesel\u012bbas apsekojuma (EHIS) tre\u0161\u0101 vi\u013c\u0146a anal\u012bze par 26 ES valst\u012bm par\u0101d\u012bja, ka aptuveni 34,3% pieaugu\u0161o regul\u0101ri pa\u0161i \u0101rst\u0113jas ar bezrecep\u0161u medikamentiem, un \u0161\u012b tendence ir\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"admin\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113 - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:description\" content=\"Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas vesel\u012bbas apsekojuma (EHIS) tre\u0161\u0101 vi\u013c\u0146a anal\u012bze par 26 ES valst\u012bm par\u0101d\u012bja, ka aptuveni 34,3% pieaugu\u0161o regul\u0101ri pa\u0161i \u0101rst\u0113jas ar bezrecep\u0161u medikamentiem, un \u0161\u012b tendence ir\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-09-01T12:02:49+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-10-16T19:27:53+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113 - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas vesel\u012bbas apsekojuma (EHIS) tre\u0161\u0101 vi\u013c\u0146a anal\u012bze par 26 ES valst\u012bm par\u0101d\u012bja, ka aptuveni 34,3% pieaugu\u0161o regul\u0101ri pa\u0161i \u0101rst\u0113jas ar bezrecep\u0161u medikamentiem, un \u0161\u012b tendence ir\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/farmacijas-zinas\\\/#listItem\",\"name\":\"Farm\\u0101cija\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/farmacijas-zinas\\\/#listItem\",\"position\":2,\"name\":\"Farm\\u0101cija\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/farmacijas-zinas\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#listItem\",\"name\":\"Deksketoprof\\u0113ns un citi bezrecep\\u0161u prets\\u0101pju l\\u012bdzek\\u013ci ikdienas praks\\u0113\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#listItem\",\"position\":3,\"name\":\"Deksketoprof\\u0113ns un citi bezrecep\\u0161u prets\\u0101pju l\\u012bdzek\\u013ci ikdienas praks\\u0113\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/farmacijas-zinas\\\/#listItem\",\"name\":\"Farm\\u0101cija\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#newsarticle\",\"name\":\"Deksketoprof\\u0113ns un citi bezrecep\\u0161u prets\\u0101pju l\\u012bdzek\\u013ci ikdienas praks\\u0113 - Medikamentu Inform\\u0101cijas Centrs\",\"headline\":\"Deksketoprof\\u0113ns un citi bezrecep\\u0161u prets\\u0101pju l\\u012bdzek\\u013ci ikdienas praks\\u0113\",\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Xeldaxin-ban-1.png\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#articleImage\"},\"datePublished\":\"2026-09-01T14:02:49+03:00\",\"dateModified\":\"2026-10-16T22:27:53+03:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#webpage\"},\"articleSection\":\"Farm\\u0101cija, Jaun\\u0101kie raksti, Medikamenti, Rekl\\u0101mraksts, Deksketoprof\\u0113ns, Rekl\\u0101mraksts\",\"dateline\":\"Published on September 1, 2026.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#webpage\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/\",\"name\":\"Deksketoprof\\u0113ns un citi bezrecep\\u0161u prets\\u0101pju l\\u012bdzek\\u013ci ikdienas praks\\u0113 - Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Prets\\u0101pju l\\u012bdzek\\u013ci ir viena no bie\\u017e\\u0101k pirktaj\\u0101m bezrecep\\u0161u z\\u0101\\u013cu grup\\u0101m jebkur\\u0101 aptiek\\u0101, un vairums klientu pie\\u0146em l\\u0113mumu par konkr\\u0113ta l\\u012bdzek\\u013ca izv\\u0113li pa\\u0161i, pirms tam nemaz nekonsult\\u0113joties ar farmaceitu. Jaun\\u0101k\\u0101 Eiropas vesel\\u012bbas apsekojuma (EHIS) tre\\u0161\\u0101 vi\\u013c\\u0146a anal\\u012bze par 26 ES valst\\u012bm par\\u0101d\\u012bja, ka aptuveni 34,3% pieaugu\\u0161o regul\\u0101ri pa\\u0161i \\u0101rst\\u0113jas ar bezrecep\\u0161u medikamentiem, un \\u0161\\u012b tendence ir\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"datePublished\":\"2026-09-01T14:02:49+03:00\",\"dateModified\":\"2026-10-16T22:27:53+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113 - Medikamentu Inform\u0101cijas Centrs","description":"Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas vesel\u012bbas apsekojuma (EHIS) tre\u0161\u0101 vi\u013c\u0146a anal\u012bze par 26 ES valst\u012bm par\u0101d\u012bja, ka aptuveni 34,3% pieaugu\u0161o regul\u0101ri pa\u0161i \u0101rst\u0113jas ar bezrecep\u0161u medikamentiem, un \u0161\u012b tendence ir","canonical_url":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/farmacija-mic.lv\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/#listItem","name":"Farm\u0101cija"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/#listItem","position":2,"name":"Farm\u0101cija","item":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#listItem","name":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113"},"previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#listItem","position":3,"name":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113","previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/#listItem","name":"Farm\u0101cija"}}]},{"@type":"NewsArticle","@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#newsarticle","name":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113 - Medikamentu Inform\u0101cijas Centrs","headline":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113","author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/09\/Xeldaxin-ban-1.png","@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#articleImage"},"datePublished":"2026-09-01T14:02:49+03:00","dateModified":"2026-10-16T22:27:53+03:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#webpage"},"isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#webpage"},"articleSection":"Farm\u0101cija, Jaun\u0101kie raksti, Medikamenti, Rekl\u0101mraksts, Deksketoprof\u0113ns, Rekl\u0101mraksts","dateline":"Published on September 1, 2026."},{"@type":"Organization","@id":"https:\/\/farmacija-mic.lv\/en\/#organization","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","url":"https:\/\/farmacija-mic.lv\/en\/"},{"@type":"Person","@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author","url":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/","name":"admin","image":{"@type":"ImageObject","@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g","width":96,"height":96,"caption":"admin"}},{"@type":"WebPage","@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#webpage","url":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/","name":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113 - Medikamentu Inform\u0101cijas Centrs","description":"Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas vesel\u012bbas apsekojuma (EHIS) tre\u0161\u0101 vi\u013c\u0146a anal\u012bze par 26 ES valst\u012bm par\u0101d\u012bja, ka aptuveni 34,3% pieaugu\u0161o regul\u0101ri pa\u0161i \u0101rst\u0113jas ar bezrecep\u0161u medikamentiem, un \u0161\u012b tendence ir","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/#website"},"breadcrumb":{"@id":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/#breadcrumblist"},"author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"creator":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"datePublished":"2026-09-01T14:02:49+03:00","dateModified":"2026-10-16T22:27:53+03:00"},{"@type":"WebSite","@id":"https:\/\/farmacija-mic.lv\/en\/#website","url":"https:\/\/farmacija-mic.lv\/en\/","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","inLanguage":"en-US","publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Medikamentu Inform\u0101cijas Centrs","og:type":"article","og:title":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113 - Medikamentu Inform\u0101cijas Centrs","og:description":"Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas vesel\u012bbas apsekojuma (EHIS) tre\u0161\u0101 vi\u013c\u0146a anal\u012bze par 26 ES valst\u012bm par\u0101d\u012bja, ka aptuveni 34,3% pieaugu\u0161o regul\u0101ri pa\u0161i \u0101rst\u0113jas ar bezrecep\u0161u medikamentiem, un \u0161\u012b tendence ir","og:url":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/","article:published_time":"2026-09-01T12:02:49+00:00","article:modified_time":"2026-10-16T19:27:53+00:00","twitter:card":"summary_large_image","twitter:title":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113 - Medikamentu Inform\u0101cijas Centrs","twitter:description":"Prets\u0101pju l\u012bdzek\u013ci ir viena no bie\u017e\u0101k pirktaj\u0101m bezrecep\u0161u z\u0101\u013cu grup\u0101m jebkur\u0101 aptiek\u0101, un vairums klientu pie\u0146em l\u0113mumu par konkr\u0113ta l\u012bdzek\u013ca izv\u0113li pa\u0161i, pirms tam nemaz nekonsult\u0113joties ar farmaceitu. Jaun\u0101k\u0101 Eiropas vesel\u012bbas apsekojuma (EHIS) tre\u0161\u0101 vi\u013c\u0146a anal\u012bze par 26 ES valst\u012bm par\u0101d\u012bja, ka aptuveni 34,3% pieaugu\u0161o regul\u0101ri pa\u0161i \u0101rst\u0113jas ar bezrecep\u0161u medikamentiem, un \u0161\u012b tendence ir"},"aioseo_meta_data":{"post_id":"22864","title":null,"description":null,"keywords":null,"keyphrases":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"limit_modified_date":false,"ai":null,"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-10-16 20:15:02","updated":"2026-10-16 20:15:02"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/\" title=\"Farm\u0101cija\">Farm\u0101cija<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tDeksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/farmacija-mic.lv\/en\/"},{"label":"Farm\u0101cija","link":"https:\/\/farmacija-mic.lv\/category\/farmacijas-zinas\/"},{"label":"Deksketoprof\u0113ns un citi bezrecep\u0161u prets\u0101pju l\u012bdzek\u013ci ikdienas praks\u0113","link":"https:\/\/farmacija-mic.lv\/en\/deksketoprofens-un-citi-bezrecepsu-pretsapju-lidzekli-ikdienas-prakse\/"}],"_links":{"self":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/comments?post=22864"}],"version-history":[{"count":1,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22864\/revisions"}],"predecessor-version":[{"id":23044,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22864\/revisions\/23044"}],"wp:attachment":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media?parent=22864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/categories?post=22864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/tags?post=22864"},{"taxonomy":"mic_flag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/mic_flag?post=22864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}